Protocol for a multicenter, prospective, real‐world study: Lecanemab in patients with early Alzheimer's disease(LEAD) in China

Abstract

Background: Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early Alzheimer's disease(AD) and received its approval for this indication in the USA 2023 and China 2024.

The paper